Your browser doesn't support javascript.
loading
Recent advances in the detection of glioblastoma, from imaging-based methods to proteomics and biosensors: A narrative review.
Hosseini, Arianaz; Ashraf, Hami; Rahimi, Fatemeh; Alipourfard, Iraj; Alivirdiloo, Vahid; Hashemi, Behnam; Yazdani, Yalda; Ghazi, Farhood; Eslami, Majid; Ameri Shah Reza, Mahdieh; Dadashpour, Mehdi.
Affiliation
  • Hosseini A; Razavi Cancer Research Center, Razavi Hospital, Mashhad, Iran.
  • Ashraf H; Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Rahimi F; Division of Clinical Laboratory, Zahra Mardani Azari Children Training, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Alipourfard I; Institute of Physical Chemistry, Polish Academy of Science, Warsaw, Poland.
  • Alivirdiloo V; Medical Doctor Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran.
  • Hashemi B; Department of Bacteriology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran.
  • Yazdani Y; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Ghazi F; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. dadashpourmehdi1400@gmail.com.
  • Eslami M; Department of Medical Bacteriology and Virology, Semnan University of Medical Sciences, Semnan, Iran.
  • Ameri Shah Reza M; Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran.
  • Dadashpour M; Department of Medical Biotechnology, Semnan University of Medical Sciences, Semnan, Iran. Farhood.ghazi190@gmail.com.
Cancer Cell Int ; 23(1): 98, 2023 May 20.
Article in En | MEDLINE | ID: mdl-37210528
Glioblastoma (GBM) is an aggressive type of cancer that originates in the cells called astrocytes, which support the functioning of nerve cells. It can develop in either the brain or the spinal cord and is also known as glioblastoma multiform. GBM is a highly aggressive cancer that can occur in either the brain or spinal cord. The detection of GBM in biofluids offers potential advantages over current methods for diagnosing and treatment monitoring of glial tumors. Biofluid-based detection of GBM focuses on identifying tumor-specific biomarkers in blood and cerebrospinal fluid. To date, different methods have been used to detect biomarkers of GBM, ranging from various imaging techniques to molecular approaches. Each method has its own strengths and weaknesses. The present review aims to scrutinize multiple diagnostic methods for GBM, with a focus on proteomics methods and biosensors. In other words, this study aims to provide an overview of the most significant research findings based on proteomics and biosensors for the diagnosis of GBM.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Prognostic_studies Language: En Journal: Cancer Cell Int Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Prognostic_studies Language: En Journal: Cancer Cell Int Year: 2023 Document type: Article